StephenGVincentMD, FAAN

Neurology • Idaho Falls, ID

Neuroimmunology/Multiple Sclerosis, Sleep Medicine

Associate Professor of Neurology, Idaho College of Osteopathic Medicine

Join to view full profile

Dr. Vincent is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vincent's full profile

Already have an account?

Office
2353 Coronado St
Idaho Falls, ID 83404
Phone+1 208-552-4823

Fax+1 208-552-4856

Summary

Dr. Stephen Vincent is a neurologist in Idaho Falls, ID and is affiliated with Mountain View Hospital. He received his medical degree from Rush Medical College in Chicago, completed his internship at Loyola and returned to Rush for his neurological training. He has been in practice for more than 25 years. He specializes in neuroimmunology/multiple sclerosis, general neurology and sleep medicine.

Education & Training

Rush University Medical CenterResidency, Neurology, 1990 - 1993
Loyola University Medical CenterInternship, Internal Medicine, 1989 - 1990
Rush Medical College of Rush University Medical CenterClass of 1989
University of Illinois at Urbana-ChampaignBS, Biology, 1985

Certifications & Licensure

ID State Medical License 1993 - 2025
WY State Medical License 1996 - 2025
IL State Medical License 1989 - 1993
American Board of Psychiatry and Neurology Neurology
National Board of Physicians and Surgeons Neurology
National Board of Physicians and Surgeons Sleep Medicine

Publications & Presentations

PubMed

22 citations
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Jiwon Oh, Anat Achiron, Elisabeth Gulowsen Celius, Christina D. Chambers, Joy Derwenskus
Multiple Sclerosis and Related Disorders. 2020-08-01

Abstracts/Posters

Postpartum Relapse After First On-study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years
...Stephen G. Vincent, MD, FAAN, ECTRIMS 2019, Stockholm, Sweden, 9/12/2019
Pregnancy Outcomes in Alemtuzumab-treated Patients With RRMS in the Phase 2 and 3 Clinical Development Program Over 16 Years
...Stephen G. Vincent, MD, FAAN, CMSC, Seattle Washington, 5/30/2019

Press Mentions

"It’s a Really Exciting Time to Be in the Contact Lens Industry”June 26th, 2021
Clinical and Experimental Optometry: A Truly International JournalOctober 26th, 2020

Committees

Chair, AAN - General Neurology Section 2008 - 2010

Research History

Safety MonitorVedolizumab-4006 An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn’s Disease Stratified at Higher Risk for Developing Complications.2016 - 2019
Principal InvestigatorSTRATEGY - A multi-center, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from Tysabri® (natalizumab) to Tecfidera® (dimethyl fumarate).2015 - 2016
Principal InvestigatorSTRATIFY-2: John Cunningham Virus (JCV) Antibody Study of Multiple Sclerosis (MS) Patients With Relapsing Forms of MS Receiving Treatment With Tysabri (STRATIFY-2)2010 - 2015
Principal InvestigatorTYGRIS: TYSABRI® Global Observational Program in Safety2006 - 2014
Principal InvestigatorCAMMS323 – A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Bete-1a(Rebif) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis2008 - 2010
Principal InvestigatorCAMMS32400507 – A Phase 3 Randomized, Rater-and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low-and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Bete-1a(Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who have Relapsed On Therapy2008 - 2010
Sub investigatorTakeda 583 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose- Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects with Mild to Moderate Diabetic Peripheral Neuropathy2007 - 2008
Sub investigatorLilly B7A-MC-MBCV.1 2005-2006 A Cross-Sectional Study to Assess the Correlation Between the Quantitative Testing of Vibration Sensation and Nerve Conduction Studies of Peroneal and Tibial Nerves in Patients with Diabetes Mellitus2005 - 2006
Sub investigatorDainippon/Advance Biologics Study AS-3201-253 2005-2006 A Multicenter, Randomized, Double Blind, Placebo-Controlled Multiple Dose Study of the Efficacy and Safety of AS-3201 in Patients with Diabetic Sensorimotor Polyneuropathy (ranirestat)2005 - 2006
Sub investigatorLilly LY333531B7A-MC-MBBR Treatment of Peripheral Neuropathy in Patients with Diabetes A Phase 3 Pivotal Clinical Trial (Ruboxistaurin mesylate)2003 - 2006
Sub investigatorLilly LY333531B7A-MC-MBCW Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes (Ruboxistaurin mesylate)2003 - 2005